Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

38 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human lymphoblastic and myeloblastic leukemia samples with and without MLL rearrangements specific and lineage specific signatures

ABSTRACT: Gene expression analysis identified a MLL translocation-specific signature of differentially expressed genes discriminating ALL and AML with and without MLL rearrangements. Gene expression signatures of acute lymphoblastic and myeloblastic leukemia samples with and without MLL rearrangements were analyzed using paired supervised analyses. Experiment Overall Design: ALL and AML patients with and without MLL rearrangements have been studied using paired class comparison (SAM) and class prediction (PAM) analyses.

ORGANISM(S): Homo sapiens

SUBMITTER: Andrea Zangrando

PROVIDER: E-GEOD-14062 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures.

Zangrando Andrea A Dell'orto Marta Campo MC Te Kronnie Geertruy G Te Kronnie Geertruy G Basso Giuseppe G

BMC medical genomics 20090623

<h4>Background</h4>The presence of MLL rearrangements in acute leukemia results in a complex number of biological modifications that still remain largely unexplained. Armstrong et al. proposed MLL rearrangement positive ALL as a distinct subgroup, separated from acute lymphoblastic (ALL) and myeloblastic leukemia (AML), with a specific gene expression profile. Here we show that MLL, from both ALL and AML origin, share a signature identified by a small set of genes suggesting a common genetic dis ...[more]

PMID: 19549311

Similar Datasets

MLL rearrangements in pediatric ALL and AML: MLL specific and lineage specific signatures

Project description:Gene expression analysis identified a MLL translocation-specific signature of differentially expressed genes discriminating ALL and AML with and without MLL rearrangements. Gene expression signatures of acute lymphoblastic and myeloblastic leukemia samples with and without MLL rearrangements were analyzed using paired supervised analyses.

2009-07-22 | GSE14062 | GEO

Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia

Project description:GEP class prediction in association with CI-FISH (42 candidate genes) and patient MRD stratification Combined Interphase FISH (CI-FISH) for 42 candidate genes and Single Nucleotide Polymorphism (SNP) arrays were applied in a series of 51 T-ALL patients enrolled in Italy into the AIEOP-BFM ALL2000 protocol and stratified by Minimal Residual Disease (MRD). In 40 cases gene expression profiles (GEP) (Affymetrix HU-133 Plus 2.0 arrays) were available. This submission represents the gene expression component of the study

2013-11-05 | E-GEOD-39816 | biostudies-arrayexpress

MLLT10 gene recombinations in pediatric T-Acute Lymphoblastic Leukemia

Project description:MLLT10, a 24 exons gene at 10p12, is known in leukemogenesis as partner of MLL or PICALM and recently NAP1L1. We identified HNRNPH1 and DDX3X, genes involved in RNA processing, as new MLLT10 partners in 2 cases of pediatric NOTCH1 positive T-ALL. HNRNPH1/5q35 encodes for a member of the ubiquitously expressed heterogeneous nuclear ribonucleoprotein (hnRNP) subfamily of RNA binding protein. DDX3X/Xp11.3, belongs to the big family of RNA helicases with a DEAD box domain. Whole genome analysis by SNPs and Combined Interphase FISH (CI-FISH) identified different co-operating lesions in the two cases. Fusion isoforms were found in both cases: interestingly all fusions retained the OM-LZ domain of MLLT10 that is needed to induce Acute Myeloid Leukemia in mice. Gene expression profiling (GEP) of the two new MLLT10 fusions was similar to PICALM-MLLT10 positive but differed from other HOXA positive T-ALL, suggesting MLLT10 fusions share a common leukemogenic pathway. Clinical data indicate relative good prognosis in T-ALL with MLLT10 variants. This submission represents the gene expression component of the study [For privacy reasons, SNP data will not be deposited].

2013-07-03 | E-GEOD-42765 | biostudies-arrayexpress

MLL partner genes confer distinct biological and clinical signatures of pediatric AML, an AIEOP study

Project description:We retrospectively analyzed AML patients enrolled in the AIEOP since 2000, 42 patients with 11q23 rearrangement were analyzed by gene expression profile Gene expression analyses were performed to compare AML MLL partner genes (AF9, AF10, AF6, ENL, ELL, Septin 6, and AF1q) Keywords: Expression data Class comparison between different AML MLL partner genes

2011-04-21 | E-GEOD-19577 | biostudies-arrayexpress

Early Relapse in ALL is identified by Time To Leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways

Project description:Gene expression analysis identified a specific signature of differentially expressed genes discriminating TTLshort and TTLlong phenotypes. Gene expression signatures of xenografted leukemia samples with different TTL phenotypes were analyzed on cohorts of pediatric BCP-ALL patients. Class comparison between TTLshort and TTLlong patient groups was analyzed by shrinkage t statistic.

2011-02-10 | E-GEOD-13576 | biostudies-arrayexpress

Expression data from human AML cell lines

Project description:Pediatric Acute Myeloid Leukemia (AML) is an aggressive and poor prognosis malignancy for which there are few effective targeted approaches, despite the numerous genetic alterations, including MLL gene rearrangements (MLL-r). The histone methyltransferase DOT1L is involved in supporting proliferation of MLL-r cells, for which a target inhibitor, Pinometostat, has been evaluated in a clinical trial recruiting pediatric MLL-r leukemic patients. However, modest clinical effects have been reported. Recent studies reported that additional leukemia subtypes lacking MLL-r are sensitive to DOT1L inhibition. Here we report that targeting DOT1L with Pinometostat sensitizes pediatric AML cells to further treatment with the multi-kinase inhibitor Sorafenib, irrespectively of MLL-r. DOT1L pharmacologic inhibition induces AML cell differentiation and modulated expression of genes with relevant roles in cancer development. Such modifications in transcriptional program impact on further treatments, inducing a strong sensitization to Sorafenib, with increased apoptosis and growth suppression of both AML cell lines and primary pediatric AML cells with diverse genotypes. We used microarrays to define differential regulation of gene expression in AML cell lines with or without MLL gene rearrangements following pharmacologic inhibition of DOT1L.

2020-07-24 | GSE144638 | GEO

Gene exprssion profile classification predicts clinical outcome in juvenile myelomonocytic leukemia

Project description:Gene expression analysis identified a specific signature of differentially expressed genes discriminating good and poor responders in JMML patients. Gene expression signatures were analyzed on two EWOG patient cohorts of pediatric JMML patients. Keywords: Expression data Class comparison between AML-like vs non-AML-like signatures in JMML patients.

2009-12-31 | E-GEOD-14858 | biostudies-arrayexpress

DNA Methylation Potential Energy Landscape Analysis of MLL-rearranged Acute Myeloid Leukemia (AML) and Normal hematopoietic precursors [WGBS]

Project description:Acute myeloid leukemia (AML) carrying MLL rearrangements. We applied WGBS and the informME analysis pipeline to investigate the role of DNA methylation stochasticity in MLL-rearranged AML.

2020-03-02 | GSE135869 | GEO

Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of cyclin dependent kinase 6 in MLL-rearranged myeloid leukemia

Project description:Acute myeloid leukemia (AML) with chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) is an aggressive subtype with low overall survival. MLL rearrangements rapidly transform hematological stem and progenitor cell (HSPC) to leukemia stem cell (LSC). Bortezomib (Velcade) is used widely in hematological malignancies. However, it is still unknown whether bortezomib possesses anti-self-renewal and anti-leukemogenesis of LSC in AML with MLL rearrangements. Here, we found that bortezomib inhibited cell proliferation, induced apoptosis, and decreased colony formation in leukemic cell lines, primary AML blasts, and MLL-AF9-transformed murine leukemic blasts. Besides, bortezomib reduced the frequency and function of LSC, inhibited the progression, and prolonged

2022-08-10 | GSE157702 | GEO

Transcription profiling of human Downs syndrome with acute lymphoblastic pediatric leukemia (DS-ALL) patients

Project description:DS-ALL is a highly heterogeneous disease with predominance of an aberrant exp. of CRLF2 cooperating with mutated JAK2; Acute lymphoblastic pediatric leukemia specimens of Down's syndrome are examined for gene expression profiles and specific genetic aberrations. Gene expression profiling and specific genetic variation analysis identify novel pathways involved in DS-ALL pathogenesis. Experiment Overall Design: Gene expression profile analysis and specific genetic data are integrated to find characteristics of DS-ALL's

2010-01-15 | E-GEOD-17459 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data